Kyowa Kirin Co., Ltd.
KYKOF
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.28B
Close$
$12.68
8.8% downside
Current Fair Value
8.8% downsideOvervalued by 8.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.28 Billion |
|---|---|
| Enterprise Value | $-233,846,133,700.00 |
| Dividend Yield | $0.42 (3.01%) |
| Earnings per Share | $128.18 |
| Beta | 0.42 |
| Outstanding Shares | 523,557,000 |
Return
| Return on Equity | 8.94% |
|---|---|
| Return on Assets | 7.24% |
| Return on Invested Capital | 13.72% |
Valuation & Multiples
| P/E Ratio | 14.3 |
|---|---|
| PEG | 17.5 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.74 |
| Enterprise Value to EBIT | 7.14 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$808.42 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$795.06 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kyowa Kirin Co., Ltd.
5,161 employees
CEO: Abdul Hafeez Mullick Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, c...